# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and lowers the price target fr...
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the ...
TD Cowen analyst Tara Bancroft maintains Ocular Therapeutix (NASDAQ:OCUL) with a Hold and lowers the price target from $11 t...
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of ...
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $16 price target.
Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy...